Pasithea Therapeutics Corp.
KTTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001841330
In the last 90 days, Pasithea Therapeutics Corp. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q2 2026, worth $8.66M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 17, 2026
- $16.0M
- Insider buysLast 90 days, $805.9K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 25
- 13F valueReported value at the end of Q2 2026
- $8.66M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$20.4M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 386.7K
- Shares sold short
- Change
- +212.1K
- +121.5% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding KTTA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KTTA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Pasithea Therapeutics Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 (view filing)8:42 PM ET | Nov 13-17 | 4 days | Coastlands Capital LP10% Owner | PPurchase | +1.67M | $0.4833 | +$805.9K | +43.5%5.50M after | 3 lots |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Coastlands Capital LP10% Owner | PPurchase | +100.0K | $0.53 | +$53.0K | +2.7%3.84M after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Steinman LawrenceDirector | PPurchase | +133.3K | $0.75 | +$100.0K | +200.9%199.7K after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Marques TiagoChief Executive Officer | PPurchase | +33.3K | $0.75 | +$25.0K | +83.3%73.3K after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Dumesnil SimonDirector | PPurchase | +33.3K | $0.75 | +$25.0K | +1,333.3%35.8K after | |
| May 14, 2025 (view filing) | May 12 | 2 days | Marques TiagoChief Executive Officer | SSale | −960 | $0.83 | −$796.8 | −2.3%40.0K after | |
| Jun 6, 2023 (view filing)9:00 PM ET | Jun 2 | 4 days | Steinman LawrenceDirector | PPurchase | +30.0K | $0.431 | +$12.9K | +2.3%1.33M after | |
| Oct 19, 2022 (view filing)5:29 PM ET | Oct 17 | 2 days | Delaney David and 2 othersOther: Member of 10% owner group | PPurchase | +1.00K | $1.11 | +$1.11K | +0.4%227.5K after | |
| Sep 30, 2022 (view filing)4:36 PM ET | Sep 28-29 | 2 days | Camac Fund, LP and 3 othersOther: Member of 10% owner group | PPurchase | +64.4K | $1.19 | +$76.3K | +3.7%1.79M after | 2 lots |
| Sep 6, 2022 (view filing)5:03 PM ET | Sep 1-6 | 5 days | Camac Fund, LP and 3 othersOther: Member of 10% owner group | PPurchase | +88.9K | $1.13 | +$100.4K | +5.4%1.72M after | 3 lots |
Top 10 13F holders, Q2 2026
See all 25 holdersThe largest institutional positions in Pasithea Therapeutics Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cable Car Capital LLC | 3,000,000 | $1.55M | 0.03% | +1,793,621+148.7% | Added |
| Stonepine Capital Management, LLC | 2,201,468 | $1.13M | 0.86% | +1,370,167+164.8% | Added |
| Jupiter Topco LLC | 2,100,000 | $1.09M | 0.00% | +2,100,000 | New |
| Adage Capital Partners GP, L.L.C. | 2,100,000 | $1.08M | 0.00% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,050,000 | $1.06M | 0.10% | +2,050,000 | New |
| Ameriprise Financial Inc | 1,864,485 | $961.0K | 0.00% | +513,589+38.0% | Added |
| Squadron Capital Management LLC | 1,000,000 | $515.4K | 0.18% | −1,100,000−52.4% | Reduced |
| AdvisorShares Investments LLC | 937,550 | $483.2K | 0.06% | +600,042+177.8% | Added |
| Vivo Capital, LLC | 465,471 | $239.9K | 0.02% | −1,634,529−77.8% | Reduced |
| Persistent Asset Partners Ltd | 290,555 | $149.8K | 0.05% | 00.0% | Unchanged |
Holders of 5% or more of KTTA
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Pasithea Therapeutics Corp..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Coastlands Capital LP | 13G/A | 11.48%3.84M shares | +1.49 ppfrom 9.99% | Feb 27, 20262 filings | Jul 1, 2026 | SEC |
| Janus Henderson Group PLC | 13G | 9.99%10.2M shares | New | Dec 8, 20251 filing | Dec 8, 2025 | SEC |
| Vivo Opportunity Fund Holdings, L.P. | 13G/A | 9.99%9.20M shares | 0.00 ppfrom 9.99% | Dec 5, 20253 filings | Nov 16, 2026 | SEC |
| Adage Capital Management, L.P. | 13G | 9.99%2.33M shares | New | Feb 12, 20261 filing | Feb 12, 2026 | SEC |
| Squadron Capital Management LLC | 13G/A | 9.90%2.33M shares | 0.00 ppfrom 9.90% | Dec 5, 20252 filings | Feb 17, 2026 | SEC |